Oxford Sciences Innovation has contributed to a series B round for Evox Therapeutics, a spinout of University of Oxford that has also added GV as a shareholder.

Evox Therapeutics, a UK-based exosome therapeutics spinout of University of Oxford, closed a £35.5m ($45.4m) series B round today backed by university venture fund Oxford Sciences Innovation (OSI).

University of Oxford also participated in the round, which was led by Redmile Group and featured GV, the corporate venturing arm of diversified conglomerate Alphabet, Panacea Healthcare Ventures, Borealis Ventures, Cowen Healthcare Investments and angel investors.

Founded in 2016, Evox Therapeutics is developing drugs for rare, life-threatening conditions with a high unmet…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?